纤维蛋白支架增强半月板修复可促进愈合与功能结局:系统综述
该系统综述纳入15项研究共438例半月板撕裂患者,其中345例接受纤维蛋白基支架增强修复。结果显示FC-PVB完全愈合率77.5%、并发症率8.2%,IKDC与Lysholm评分显著改善;与非增强修复相比,纤维蛋白增强修复愈合与功能更优。
要点
- 纤维蛋白基增强修复半月板撕裂完全愈合率77.5%,并发症率8.2%。
- FC-PVB改善IKDC与Lysholm评分,但Tegner评分未显著改善。
- 与非增强修复相比,纤维蛋白增强修复的愈合与功能结局更优。
核心结论
- 纤维蛋白基增强修复半月板撕裂表现出高愈合率、低并发症率和改善的临床结局评分。
- 与非增强修复相比,纤维蛋白基支架获得更好的愈合与功能。
- FC-PVB改善症状缓解与功能恢复,仅FC-BMAC显示活动水平改善。
研究设计与样本
- 系统综述,证据等级4级,遵循PRISMA指南检索PubMed、Embase和Ovid MEDLINE至2025年10月15日。
- 共纳入15项研究,438例半月板撕裂患者,撕裂多位于无血管区。
- 345例接受纤维蛋白基增强修复,其余未接受增强。
主要发现
- FC-PVB组完全愈合77.5%、部分愈合12.2%、失败10.3%。
- FC-PVB组并发症发生率8.2%,包括感觉异常和再损伤;2.6%报告持续性膝痛。
- FC-PVB研究中IKDC和Lysholm评分显著改善,Tegner评分未显著改善。
- 其他纤维蛋白基方法在所有评分上均显示一致改善。
- 与非增强修复相比,纤维蛋白基增强修复结局更优。
关键数值与推荐
- 纤维蛋白基方法包括:外周静脉血纤维蛋白凝块(FC-PVB,n=252)、骨髓抽吸浓缩物纤维蛋白凝块(FC-BMAC,n=30)、富血小板纤维蛋白(PRF,n=15)、PRF联合富血小板血浆(PRF+PRP,n=48)。
临床怎么用
- 对于半月板撕裂(尤其无血管区)修复,可考虑使用纤维蛋白基支架增强以促进愈合和改善功能。
- FC-PVB可作为增强选项改善症状与功能恢复,FC-BMAC可能有助于活动水平提升。
局限性
- 证据等级为4级,纳入研究以单臂或非随机对照为主,异质性可能影响结论强度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biologic augmentation techniques, such as fibrin-based scaffolds, have been proposed to enhance healing of meniscal tears, particularly in avascular zones. However, clinical outcomes remain variably reported. STUDY DESIGN: Systematic review; Level of evidence, 4. PURPOSE: To evaluate the healing rate, complication rate, and patient-reported outcome scores after meniscal repair augmented with fibrin-based scaffolds. METHODS: A systematic review was conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, searching PubMed, Embase, and Ovid MEDLINE through October 15, 2025. Studies evaluating fibrin-based augmentation during meniscal repair were included. Primary outcomes were healing and complication rates. Secondary outcomes included International Knee Documentation Committee (IKDC), Lysholm, and Tegner scores. RESULTS: Of 757 studies, 15 met inclusion criteria, comprising 438 patients with meniscal tears in mostly avascular zones. Of these, 345 underwent fibrin-based augmentation; the rest did not. There were 4 fibrin-based methods identified: fibrin clot from peripheral venous blood (FC-PVB; n = 252), fibrin clot from bone marrow aspirate concentrate (FC-BMAC; n = 30), platelet-rich fibrin (PRF; n = 15), and PRF combined with platelet-rich plasma (PRF+PRP; n = 48). Among patients who received FC-PVB, 77.5% achieved complete healing, 12.2% partial healing, and 10.3% failure. Complications occurred in 8.2% of patients who received FC-PVB and included paresthesia and reinjuries; 2.6% reported persistent knee pain. In FC-PVB studies, significant improvements were seen in IKDC and Lysholm scores but not in Tegner scores. Other fibrin-based methods showed consistent improvements across all scores. Compared to nonaugmented repair, fibrin-based augmentation yielded superior outcomes. CONCLUSION: Fibrin-based augmentation demonstrated high healing rates, low complication rates, and improved clinical outcome scores. Compared to nonaugmented repair, fibrin-based scaffolds achieved better healing and function. FC-PVB enhanced symptom relief and functional recovery, while only FC-BMAC showed improvements in activity levels.
引用
- Skaik K, Kahlon H, Bouchard MD, et al. Fibrin-Based Scaffold Augmentation During Meniscal Repair May Enhance Healing and Functional Outcomes: A Systematic Review. Am J Sports Med. 2026. PMID: 42233488. doi:10.1177/03635465261440395
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。